These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 16271338)
21. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209 [TBL] [Abstract][Full Text] [Related]
22. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Katzka DA; Paoletti V; Leite L; Castell DO Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731 [TBL] [Abstract][Full Text] [Related]
23. Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy. Anandasabapathy S; Jaffin BW Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):563-70. PubMed ID: 16944654 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery. Hata M; Shiono M; Sekino H; Furukawa H; Sezai A; Iida M; Yoshitake I; Hattori T; Wakui S; Taoka M; Negishi N; Sezai Y Surg Today; 2006; 36(2):131-4. PubMed ID: 16440158 [TBL] [Abstract][Full Text] [Related]
25. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Thomson AB Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051 [TBL] [Abstract][Full Text] [Related]
26. Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice? Juul-Hansen P; Rydning A Scand J Gastroenterol; 2003 Dec; 38(12):1200-3. PubMed ID: 14750637 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system. Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412 [TBL] [Abstract][Full Text] [Related]
28. 24 Versus 48-hour bravo pH monitoring. Chander B; Hanley-Williams N; Deng Y; Sheth A J Clin Gastroenterol; 2012 Mar; 46(3):197-200. PubMed ID: 21959323 [TBL] [Abstract][Full Text] [Related]
29. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904 [TBL] [Abstract][Full Text] [Related]
30. Performance, tolerability, and symptoms related to prolonged pH monitoring using the Bravo system in Mexico. Remes-Troche JM; Ibarra-Palomino J; Carmona-Sánchez RI; Valdovinos MA Am J Gastroenterol; 2005 Nov; 100(11):2382-6. PubMed ID: 16279888 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. Welage LS; Berardi RR J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250 [TBL] [Abstract][Full Text] [Related]
32. On-demand PPI requirements in patients with endoscopy-negative GERD. Juul-Hansen P; Rydning A J Clin Gastroenterol; 2004 Oct; 38(9):746-9. PubMed ID: 15365398 [TBL] [Abstract][Full Text] [Related]
33. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Poe RH; Kallay MC Chest; 2003 Mar; 123(3):679-84. PubMed ID: 12628862 [TBL] [Abstract][Full Text] [Related]
35. [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease]. Maev IV; Kucheriavyĭ IuA; Danilin MS Eksp Klin Gastroenterol; 2003; (5):10-2, 192. PubMed ID: 14621603 [TBL] [Abstract][Full Text] [Related]
36. BRAVO esophageal pH monitoring: more cost-effective than empiric medical therapy for suspected gastroesophageal reflux. Afaneh C; Zoghbi V; Finnerty BM; Aronova A; Kleiman D; Ciecierega T; Crawford C; Fahey TJ; Zarnegar R Surg Endosc; 2016 Aug; 30(8):3454-60. PubMed ID: 26537906 [TBL] [Abstract][Full Text] [Related]
37. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. Horn J Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214 [TBL] [Abstract][Full Text] [Related]
38. [What is the utility of proton pump inhibitor testing in non-cardiac chest pain?]. Huamán JW; Aliaga V; Domenech G; Videla S; Saperas E Gastroenterol Hepatol; 2014 Oct; 37(8):452-61. PubMed ID: 24725608 [TBL] [Abstract][Full Text] [Related]
39. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS? Azzam RS Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]